Press Releases :: Nighthawk Biosciences, Inc. (SCPX)

May 11, 2015 2:04pm EDT

CORRECTING and REPLACING -- Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)

May 11, 2015 2:04pm EDT

Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)

Apr 22, 2015 8:00am EDT

Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting

Apr 15, 2015 8:00am EDT

Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting

Mar 27, 2015 8:30am EDT

Heat Biologics Announces Financial Results for the Year Ended December 31, 2014

Mar 16, 2015 2:28pm EDT

Heat Biologics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Over-Allotment Option

Mar 10, 2015 9:42pm EDT

Heat Biologics, Inc. Announces Pricing of Public Offering of $10,660,000 of Common Stock

Mar 10, 2015 5:07pm EDT

Heat Biologics, Inc. Announces Proposed Public Offering of Common Stock

Mar 09, 2015 8:00am EDT

Heat Biologics, Inc. Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer

Feb 26, 2015 8:00am EST

Heat Biologics Provides Update at Key Opinion Leader Event

rss_feed News RSS